Basic Information
| LncRNA/CircRNA Name | XIST |
| Synonyms | XIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66 |
| Region | GRCh38_X:73820651-73852753 |
| Ensemble | ENSG00000229807 |
| Refseq | NR_001564 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, RIP, Western blot etc. |
| Sample | Human osteosarcoma cell lines (U2OS, Saos-2, 143B, MG-63, HOS), OS tissues |
| Expression Pattern | up-regulated |
| Function Description | Taking all into account, Xist may function in promoting OS cell proliferation and may potentially serve as a novel biomarker and therapeutic target for OS.Due to recent advancements in multimodal treatments, the 5-year survival rate of OS patients has significantly improved over the past decades. |
| Pubmed ID | 29254174 |
| Year | 2017 |
| Title | Upregulation of long noncoding RNA Xist promotes proliferation of osteosarcoma by epigenetic silencing of P21. |
External Links
| Links for XIST | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |